Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients

Jian Wang, Wenju Lu, Wei Wang, Nuofu Zhang, Hua Wu, Chunli Liu, Xiuqing Chen, Yonghua Chen, Yuqin Chen, Qian Jiang, Lei Xu, Lichun Tian, Pixin Ran, Nanshan Zhong

Research output: Contribution to journalArticle

Abstract

Background: Pulmonary hypertension (PH) is a lethal disease with no cure currently available. Sodium Tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the major active component from salvia miltiorrhiza, a kind of Chinese herbal medicine. We investigate the efficacy of STS towards treatment of PH patients. Methods and results: Five hospitalized patients were randomly enrolled for this study. These patients were suffering from various types of serious PH without getting sufficient benefits from sildenafil treatment (20 mg tid) for at least three months. The efficacy of STS on PH was evaluated by measuring the pulmonary arterial systolic pressure (PASP), RV size by echocardiography, 6-minute walking distance (6MWD), Borg dyspnea score, and WHO functional class of PH. Patients aged from 17 to 46 (average 33±11) years old, pulmonary arterial systolic pressure (PASP) ranged from 60 to 140 mmHg, RV size ranged from 25 to 39 mm were included in study. At the endpoint of observation for 8 weeks of STS infusion, they obtained reduction of PASP in the range of 14-45 (average 28.6±12.5) mmHg, RV size in the range of 0-10 (average 4.2±1.6). All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II. Conclusions: These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil

Original languageEnglish (US)
Pages (from-to)169-172
Number of pages4
JournalJournal of Thoracic Disease
Volume5
Issue number2
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Therapeutic Uses
Pulmonary Hypertension
Arterial Pressure
Blood Pressure
Dyspnea
Lung
Walking
Salvia miltiorrhiza
Herbal Medicine
tanshinone II A sodium sulfonate
Echocardiography
Observation
Exercise
Water
Therapeutics

Keywords

  • Pulmonary arterial hypertension
  • Pulmonary hypertension
  • Tanshinone iia sulfonate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients. / Wang, Jian; Lu, Wenju; Wang, Wei; Zhang, Nuofu; Wu, Hua; Liu, Chunli; Chen, Xiuqing; Chen, Yonghua; Chen, Yuqin; Jiang, Qian; Xu, Lei; Tian, Lichun; Ran, Pixin; Zhong, Nanshan.

In: Journal of Thoracic Disease, Vol. 5, No. 2, 04.2013, p. 169-172.

Research output: Contribution to journalArticle

Wang, J, Lu, W, Wang, W, Zhang, N, Wu, H, Liu, C, Chen, X, Chen, Y, Chen, Y, Jiang, Q, Xu, L, Tian, L, Ran, P & Zhong, N 2013, 'Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients', Journal of Thoracic Disease, vol. 5, no. 2, pp. 169-172. https://doi.org/10.3978/j.issn.2072-1439.2013.02.04
Wang, Jian ; Lu, Wenju ; Wang, Wei ; Zhang, Nuofu ; Wu, Hua ; Liu, Chunli ; Chen, Xiuqing ; Chen, Yonghua ; Chen, Yuqin ; Jiang, Qian ; Xu, Lei ; Tian, Lichun ; Ran, Pixin ; Zhong, Nanshan. / Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients. In: Journal of Thoracic Disease. 2013 ; Vol. 5, No. 2. pp. 169-172.
@article{2a7e58485c9c4d139b0f9e5680b60fc9,
title = "Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients",
abstract = "Background: Pulmonary hypertension (PH) is a lethal disease with no cure currently available. Sodium Tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the major active component from salvia miltiorrhiza, a kind of Chinese herbal medicine. We investigate the efficacy of STS towards treatment of PH patients. Methods and results: Five hospitalized patients were randomly enrolled for this study. These patients were suffering from various types of serious PH without getting sufficient benefits from sildenafil treatment (20 mg tid) for at least three months. The efficacy of STS on PH was evaluated by measuring the pulmonary arterial systolic pressure (PASP), RV size by echocardiography, 6-minute walking distance (6MWD), Borg dyspnea score, and WHO functional class of PH. Patients aged from 17 to 46 (average 33±11) years old, pulmonary arterial systolic pressure (PASP) ranged from 60 to 140 mmHg, RV size ranged from 25 to 39 mm were included in study. At the endpoint of observation for 8 weeks of STS infusion, they obtained reduction of PASP in the range of 14-45 (average 28.6±12.5) mmHg, RV size in the range of 0-10 (average 4.2±1.6). All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II. Conclusions: These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil",
keywords = "Pulmonary arterial hypertension, Pulmonary hypertension, Tanshinone iia sulfonate",
author = "Jian Wang and Wenju Lu and Wei Wang and Nuofu Zhang and Hua Wu and Chunli Liu and Xiuqing Chen and Yonghua Chen and Yuqin Chen and Qian Jiang and Lei Xu and Lichun Tian and Pixin Ran and Nanshan Zhong",
year = "2013",
month = "4",
doi = "10.3978/j.issn.2072-1439.2013.02.04",
language = "English (US)",
volume = "5",
pages = "169--172",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "2",

}

TY - JOUR

T1 - Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients

AU - Wang, Jian

AU - Lu, Wenju

AU - Wang, Wei

AU - Zhang, Nuofu

AU - Wu, Hua

AU - Liu, Chunli

AU - Chen, Xiuqing

AU - Chen, Yonghua

AU - Chen, Yuqin

AU - Jiang, Qian

AU - Xu, Lei

AU - Tian, Lichun

AU - Ran, Pixin

AU - Zhong, Nanshan

PY - 2013/4

Y1 - 2013/4

N2 - Background: Pulmonary hypertension (PH) is a lethal disease with no cure currently available. Sodium Tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the major active component from salvia miltiorrhiza, a kind of Chinese herbal medicine. We investigate the efficacy of STS towards treatment of PH patients. Methods and results: Five hospitalized patients were randomly enrolled for this study. These patients were suffering from various types of serious PH without getting sufficient benefits from sildenafil treatment (20 mg tid) for at least three months. The efficacy of STS on PH was evaluated by measuring the pulmonary arterial systolic pressure (PASP), RV size by echocardiography, 6-minute walking distance (6MWD), Borg dyspnea score, and WHO functional class of PH. Patients aged from 17 to 46 (average 33±11) years old, pulmonary arterial systolic pressure (PASP) ranged from 60 to 140 mmHg, RV size ranged from 25 to 39 mm were included in study. At the endpoint of observation for 8 weeks of STS infusion, they obtained reduction of PASP in the range of 14-45 (average 28.6±12.5) mmHg, RV size in the range of 0-10 (average 4.2±1.6). All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II. Conclusions: These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil

AB - Background: Pulmonary hypertension (PH) is a lethal disease with no cure currently available. Sodium Tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the major active component from salvia miltiorrhiza, a kind of Chinese herbal medicine. We investigate the efficacy of STS towards treatment of PH patients. Methods and results: Five hospitalized patients were randomly enrolled for this study. These patients were suffering from various types of serious PH without getting sufficient benefits from sildenafil treatment (20 mg tid) for at least three months. The efficacy of STS on PH was evaluated by measuring the pulmonary arterial systolic pressure (PASP), RV size by echocardiography, 6-minute walking distance (6MWD), Borg dyspnea score, and WHO functional class of PH. Patients aged from 17 to 46 (average 33±11) years old, pulmonary arterial systolic pressure (PASP) ranged from 60 to 140 mmHg, RV size ranged from 25 to 39 mm were included in study. At the endpoint of observation for 8 weeks of STS infusion, they obtained reduction of PASP in the range of 14-45 (average 28.6±12.5) mmHg, RV size in the range of 0-10 (average 4.2±1.6). All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II. Conclusions: These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil

KW - Pulmonary arterial hypertension

KW - Pulmonary hypertension

KW - Tanshinone iia sulfonate

UR - http://www.scopus.com/inward/record.url?scp=84876810207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876810207&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2072-1439.2013.02.04

DO - 10.3978/j.issn.2072-1439.2013.02.04

M3 - Article

VL - 5

SP - 169

EP - 172

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 2

ER -